Alkermes plc. (ALKS): EBITDA
$281.12M
Year ended 2025-12-31
$178.89M
Trailing 12 months to 2026-06-30
+57.6%
3-year compound annual growth
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $281.12M | -37.4% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $449.17M | -8.2% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $489.05M | +581.4% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $71.77M | -59.3% | 2025-02-12, From 2022-01-01 |
| 2021-12-31 | $176.40M | n/m | 2024-02-21, From 2021-01-01 |
| 2020-12-31 | -$30.57M | n/m | 2023-02-16, From 2020-01-01 |
| 2019-12-31 | -$95.07M | n/m | 2022-02-16, From 2019-01-01 |
| 2018-12-31 | $4.53M | n/m | 2021-02-11, From 2018-01-01 |
| 2017-12-31 | -$49.38M | n/m | 2020-02-13, From 2017-01-01 |
| 2016-12-31 | -$114.41M | n/m | 2019-02-15, From 2016-01-01 |
| 2015-12-31 | -$138.71M | n/m | 2018-02-16, From 2015-01-01 |
| 2014-12-31 | $10.94M | n/a | 2017-02-17, From 2014-01-01 |
| No annual figure between 2012-03-31 and 2014-12-31. | |||
| 2012-03-31 | -$40.40M | n/m | 2013-05-23, From 2011-04-01 |
| 2011-03-31 | -$36.98M | n/m | 2013-05-23, From 2010-04-01 |
| 2010-03-31 | -$18.01M | n/a | 2012-05-18, From 2009-04-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Alkermes plc. (ALKS) | 2025-12-31 | $281.12M | -37.4% |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $245.91M | +57.6% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $905.75M | n/m |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | $272.00M | +403.7% |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $340.68M | -7.2% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | -$655.26M | n/m |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | -$298.59M | n/m |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $202.51M | +196.4% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $120.55M | n/m |
Compare ALKS, PAHC, PTCT, INDV side by side · Screen every company in Pharmaceutical Preparations ↗